Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein
暂无分享,去创建一个
R. Hamatake | J. Vamathevan | T. Shimada | M. Thomson | S. Van Horn | Elizabeth Thomas | J. Pouliot | D. Parks | Mi Xie | Joseph H Horton | John Johnson | D. Krull | A. Mathis | Y. Morikawa | Richard E. Peterson | Zhiping Z Xiong | A. Peat | Zhiping Xiong | Amanda M. Mathis
[1] Zhengrong Zhu,et al. Encoded Library Technology Screening of Hepatitis C Virus NS4B Yields a Small-Molecule Compound Series with In Vitro Replicon Activity , 2015, Antimicrobial Agents and Chemotherapy.
[2] H. Fleury,et al. Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia , 2014, Journal of medical virology.
[3] D. J. Price,et al. Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein. , 2014, Bioorganic & medicinal chemistry letters.
[4] C. Rice,et al. Identification of AP80978, a Novel Small-Molecule Inhibitor of Hepatitis C Virus Replication That Targets NS4B , 2014, Antimicrobial Agents and Chemotherapy.
[5] D. J. Price,et al. Hepatitis C replication inhibitors that target the viral NS4B protein. , 2014, Journal of medicinal chemistry.
[6] Ramesh Kakarla,et al. Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B. , 2014, Journal of medicinal chemistry.
[7] Huiling Yang,et al. Highly potent HCV NS4B inhibitors with activity against multiple genotypes. , 2014, Journal of medicinal chemistry.
[8] A. Lam,et al. Discovery of a novel class of potent HCV NS4B inhibitors: SAR studies on piperazinone derivatives. , 2014, Journal of medicinal chemistry.
[9] H. Mo,et al. Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates. , 2013, Antiviral research.
[10] R. Hamatake,et al. Preclinical Characterization of GSK2336805, a Novel Inhibitor of Hepatitis C Virus Replication That Selects for Resistance in NS5A , 2013, Antimicrobial Agents and Chemotherapy.
[11] R. Hamatake,et al. In Vitro Characterization of GSK2485852, a Novel Hepatitis C Virus Polymerase Inhibitor , 2013, Antimicrobial Agents and Chemotherapy.
[12] Choongho Lee,et al. A hepatitis C virus NS4B inhibitor suppresses viral genome replication by disrupting NS4B’s dimerization/multimerization as well as its interaction with NS5A , 2013, Virus Genes.
[13] S. Peltz,et al. Identification of PTC725, an Orally Bioavailable Small Molecule That Selectively Targets the Hepatitis C Virus NS4B Protein , 2013, Antimicrobial Agents and Chemotherapy.
[14] B. Pearlman. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. , 2012, The Lancet. Infectious diseases.
[15] D. J. Price,et al. Imidazo[1,2-a]pyridines That Directly Interact with Hepatitis C NS4B: Initial Preclinical Characterization. , 2012, ACS medicinal chemistry letters.
[16] Izuru Ando,et al. Preclinical Characterization of JTK-853, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase , 2012, Antimicrobial Agents and Chemotherapy.
[17] R. Hamatake,et al. Hepatitis C genotype 1a replicon improved through introduction of fitness mutations. , 2012, BioTechniques.
[18] X. Tong,et al. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa‐2b , 2012, Journal of viral hepatitis.
[19] M. Imamura,et al. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo , 2011, Hepatology.
[20] R. Bartenschlager,et al. NS4B Self-Interaction through Conserved C-Terminal Elements Is Required for the Establishment of Functional Hepatitis C Virus Replication Complexes , 2011, Journal of Virology.
[21] K. Konan,et al. Conserved GXXXG- and S/T-Like Motifs in the Transmembrane Domains of NS4B Protein Are Required for Hepatitis C Virus Replication , 2011, Journal of Virology.
[22] F. Penin,et al. Amphipathic α-Helix AH2 Is a Major Determinant for the Oligomerization of Hepatitis C Virus Nonstructural Protein 4B , 2010, Journal of Virology.
[23] C. Roberts,et al. A small molecule inhibits HCV replication and alters NS4B's subcellular distribution. , 2010, Antiviral research.
[24] J. Guillén,et al. Interaction of the N-terminal segment of HCV protein NS5A with model membranes. , 2010, Biochimica et biophysica acta.
[25] Darius Moradpour,et al. Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory , 2010, Reviews in medical virology.
[26] A. Gonzalez-Alvarez,et al. A membranotropic region in the C-terminal domain of hepatitis C virus protein NS4B interaction with membranes. , 2010, Biochimica et biophysica acta.
[27] N. Cho,et al. Identification of a Class of HCV Inhibitors Directed Against the Nonstructural Protein NS4B , 2010, Science Translational Medicine.
[28] S. Jia,et al. Formation and function of hepatitis C virus replication complexes require residues in the carboxy-terminal domain of NS4B protein. , 2009, Virology.
[29] F. Penin,et al. An Amphipathic α-Helix at the C Terminus of Hepatitis C Virus Nonstructural Protein 4B Mediates Membrane Association , 2009, Journal of Virology.
[30] D. Douglas,et al. HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti‐hepatitis C virus activity In Vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus , 2009, Hepatology.
[31] A. Thompson,et al. Biochemical characterization of recombinant hepatitis C virus nonstructural protein 4B: evidence for ATP/GTP hydrolysis and adenylate kinase activity. , 2009, Biochemistry.
[32] Todd M. Allen,et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients , 2008, Hepatology.
[33] S. Quake,et al. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis , 2008, Nature Biotechnology.
[34] K. Blight,et al. A Genetic Interaction between Hepatitis C Virus NS4B and NS3 Is Important for RNA Replication , 2008, Journal of Virology.
[35] R. Chopra,et al. Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796 , 2008, Antimicrobial Agents and Chemotherapy.
[36] A. Kosaka,et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. , 2008, The Journal of antimicrobial chemotherapy.
[37] Thomas Lengauer,et al. Structural and functional comparison of the non-structural protein 4B in flaviviridae. , 2007, Journal of molecular graphics & modelling.
[38] M. Ronaghi,et al. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. , 2007, Genome research.
[39] Tara L. Kieffer,et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. , 2007, Gastroenterology.
[40] C. Grönwall,et al. Dual topology of the processed hepatitis C virus protein NS4B is influenced by the NS5A protein. , 2006, The Journal of general virology.
[41] Guann-Yi Yu,et al. Palmitoylation and Polymerization of Hepatitis C Virus NS4B Protein , 2006, Journal of Virology.
[42] S. Harper,et al. Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase , 2005, Xenobiotica; the fate of foreign compounds in biological systems.
[43] C. Rice,et al. An N-Terminal Amphipathic Helix in Hepatitis C Virus (HCV) NS4B Mediates Membrane Association, Correct Localization of Replication Complex Proteins, and HCV RNA Replication , 2004, Journal of Virology.
[44] M. Elazar,et al. A Nucleotide Binding Motif in Hepatitis C Virus (HCV) NS4B Mediates HCV RNA Replication , 2004, Journal of Virology.
[45] Steven R. LaPlante,et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus , 2003, Nature.
[46] M. Kieny,et al. Protein-Protein Interactions between Hepatitis C Virus Nonstructural Proteins , 2003, Journal of Virology.
[47] P. Bonneau,et al. An NS 3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus , 2003 .
[48] S. Piccininni,et al. Modulation of the Hepatitis C Virus RNA-dependent RNA Polymerase Activity by the Non-Structural (NS) 3 Helicase and the NS4B Membrane Protein* , 2002, The Journal of Biological Chemistry.
[49] Dieter Häussinger,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.
[50] L. Bianchi,et al. Expression of Hepatitis C Virus Proteins Induces Distinct Membrane Alterations Including a Candidate Viral Replication Complex , 2002, Journal of Virology.
[51] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[52] C. Rice,et al. The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. , 2001, Virology.
[53] L. Seeff,et al. Natural history of hepatitis C , 1997, Hepatology.
[54] R. W. Mccollum. The natural history of hepatitis. , 1969, Bulletin of the New York Academy of Medicine.